Advertisement

Picture [iito] No Tracking 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 1037 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 7 8 9 10 11  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
BioInvent–Merck (DE): bioreactors, 201704 supply full line of Mobius single-use bioreators to BioInvent upstream facility in Lund 2017-04-20
Lytix Biopharma–SEVERAL: investment, 201704 private placement NOK60m incl NOK6m from Norwegian Cancer Society 2017-04-20
Cobra Biologics–Zyme Communications: public relations, 201704 service existent by Zyme 2017-04-18
MOCON–AMETEK: investment, 201704– acquisition of MOCON Inc for aggregate enterprise value of $182m 2017-04-17
Biosyntia–FGen: biological vitamin production, 201704– collob developm of microbial strains for production of specific B vitamins 2017-04-05
Ahma–Eurofins: investment, 201704 acquisition of 2nd largest Finnish environmental testing lab Ahma Group by Eurofins 2017-04-04
MKS Instruments–Sartorius: investment, 201704 acquisition $72.5m of MKS Instruments AB (Umetrics) by Sartorius Stedim Biotech 2017-04-03
Ramboll–Eurofins: investment, 201704 acquisition of analytical lab business of Ramboll in Finland by Eurofins 2017-04-03
VBM Laboratoriet–Eurofins: investment, 201703 acquisition of VBM by Eurofins 2017-03-24
AvroBio–Univ Lund: gene therapy, 201703– license + collab agreement €na for Gaucher disease gene therapy 2017-03-22
BerGenBio–SEVERAL: investment, 201703–201704 IPO NOK400m with 16m new shares at NOK25/Share at Oslo Stock Exchange 2017-03-08
Orphazyme–SEVERAL: investment, 201703 financing round €14m incl new investors LSP + ALS Investment Fund 2017-03-08
Spero Therapeutics–Lundbeck: investment, 201703 financing round Series C totalling $51.7m incl existing investor Lundbeckfonden Ventures 2017-03-08
Spero Therapeutics–SEVERAL: investment, 201703 financing round Series C $51.7m preferred shares led by new investor GV 2017-03-08
Faron Pharmaceuticals–Consilium: public relations, 201703 service existent by CSC 2017-03-01
Faron Pharmaceuticals–SEVERAL: investment, 201702–201703 capital increase £5m w placing of 1.36m + subscription of 60k shares at350p/share 2017-02-28
Oncopeptides–SEVERAL: investment, 201702 IPO €72.5m at Nasdaq Stockholm 2017-02-22
Bayer–Yara: digital farming, 201702– collab + license ww to ImageIT mobile imaging technology for plant monitoring + farming recommendations 2017-02-20
Modus Therapeutics–SEVERAL: investment, 201702 financing round SEK32m ($3.6m) from existing investors KDev + Östersjöstiftelsen + Praktikerinvest 2017-02-20
Immunicum–MacDougall Biomedical Communications: public relations, 201702 service existent by MacDougall 2017-02-13
Evotec–Novo Group: investment, 201702 strategic investment of €90.3m 13.15m new Evotec shares at €6.87/share resulting in 8.9% ownership by Novo A/S 2017-02-09
Lysogene–Novo Group: investment, 201702 existing investor Novo A/S 2017-02-08
Prexton Therapeutics–Forbion: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba 2017-02-07
Prexton Therapeutics–Merck (DE): investment, 201702 financing round Series B totalling €29m incl returning co-investor Merck Ventures 2017-02-07
Prexton Therapeutics–Seroba: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba 2017-02-07
Prexton Therapeutics–SEVERAL: investment, 201702 financing round Series B €29m co-led by new investors Forbion + Seroba 2017-02-07
Prexton Therapeutics–Sunstone Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Sunstone Capital 2017-02-07
Prexton Therapeutics–Ysios Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Ysios Capital 2017-02-07
Novo Group–Univ Oxford: antidiabetic, 201701– collab research focused on type 2 diabetes incl establishing Novo Nordisk Research Centre Oxford 2017-01-30
Cellectricon–Censo Biotechnologies: drug discovery services, 201701– collab offer joint tech access program for human iPSC-based discovery services 2017-01-26
Lundbeck–IBM: healthcare informatics, 201701– collab using Watson Health technology + cloud to advance CNS drug development 2017-01-25
Macrophage Pharma–Aglaia: investment, 201701 financing round Series A totalling £9m incl co-investors Novo Seeds + Aglaia 2017-01-09
Macrophage Pharma–Chroma Therapeutics: cancer immunotherapy, 201701 acquisition of ESM technology w discovery stage theapeutic assets by Macrophage 2017-01-09
Macrophage Pharma–Novo Group: investment, 201701 financing round Series A totalling £9m incl co-investors Novo Seeds + Aglaia 2017-01-09
Macrophage Pharma–SEVERAL: investment, 201701 financing round Series A £9m led by CRT Pioneer Fund + incl Novo Seeds + Aglaia 2017-01-09
Macrophage Pharma–Sixth Element Capital: investment, 201701 financing round Series A totalling £9m incl lead investor CRT Pioneer Fund 2017-01-09
HepaRegenix–Germany (govt): investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–High-Tech Gründerfonds: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–Novo Group: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–SEVERAL: investment, 201701 financing round Series A €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
Nerre Therapeutics–SEVERAL: investment, 201701 financing round Series B £23m from Fountain Healthcare + Forbion + Orbimed + Novo + Advent 2017-01-05
C.B.S. Scientific–Genetrix (ES): investment, 201612 acquisition $900k of C.B.S. Scientific Company for $540k cash + $360k in shares by Sygnis AG 2016-12-21
CMC Biologics–Asahi Glass: investment, 201612– acquisition JPY60b of 100% of CMC Biologics by Asahi Glass 2016-12-19
Cantargia–SMS-Oncology: clinical research services, 201612– supply CRO service for ph1/2a study with Cantargia’s lead compound CAN04 2016-12-16
Genome Diagnostics–Illumina: DNA sequencing, 201612– collab GenDx non-excl reseller of Illumina porudcts for HLA sequencing in several countries 2016-12-13
Vaccibody–SEVERAL: investment, 201612 private placement NOK220m (€24m) with 880k new shares at NOK250/share to new + existing investors 2016-12-09
Nordic Nanovector–SEVERAL: investment, 201612 private placement NOK498.7m ($59.3m) with 4.4m new shares at 114NOK/share 2016-12-07
Bayer–FaunaPhotonics: digital farming technology, 201612– collab developm sensor technology for insect pest monitoring w Bayer CropScience 2016-12-05
OxThera–SEVERAL: investment, 201611 financing round €32m co-led by Life Sciences Partners + Ysios Capital + Sunstone Capital + Flerie Invest 2016-11-29
SenzaGen–EU (govt): grant, 201611– Horizon 2020 grant €2.4m to develop GARDair test 2016-11-29
Noona Healthcare–SEVERAL: investment, 201611 seed financing round €1.5m from led by Inventure 2016-11-23
Quanterix–UmanDiagnostics: molecular diagnostics, 201611– collab developm blood-based test for brain injury using NF-light ELISA + Simoa technology 2016-11-21
CorWave–SEVERAL: investment, 2013 financing round Series A 2016-11-04
CorWave–SEVERAL: investment, 201611 financing round Series B €15.5m led by new investor Novo Seeds 2016-11-04
Leo Pharma–MorphoSys: therapeutic antibodies, 201611– collab strategic alliance to develop ABs in dermatology using Ylanthia technology 2016-11-02
Medivir–Tetralogic Pharmaceuticals: cancer drugs, 201611 acquisition of remetinostat + birinapant + all related IP + data by Medivir 2016-11-02
Acesion Pharma–SEVERAL: investment, 201611 financing round Series A €9.1m from Wellcome Trust + Novo Seeds 2016-11-01
Medivir–Karo Pharma: investment, 201611–201612 acquisition of BioPhausia AB (Nordic Brands) for SEK908m cash+debt free in cash net SEK868m 2016-11-01
BoneSupport–SEVERAL: investment, 201610 raised $47m (SEK327m) in combination of equity + debt finance 2016-10-27
Nordic Nanovector–Wilex: antibody-drug conjugates, 201610– collab developm of ADCs for leukemias with Heidelberg Pharma 2016-10-26
Oasmia–SEVERAL: investment, 201610 private placement SEK70m w 8.75m new shares at SEK8/share to professional + qualified investors 2016-10-21
Ascendis Pharma–SEVERAL: investment, 201610 public offering $120m with 6.3m ADSs at $19/ADS 2016-10-18
LegoChem–Nordic Nanovector: antibody-drug conjugates, 201610– collab to develop CD37-targeting ADCs for leukemias 2016-10-10
Kibion–Mayoly Spindler: investment, 201610 acquisition of Kibion AB by Mayoly Spindler 2016-10-05
Brainshake–SEVERAL: investment, 201610 financing round Series B €2m 2016-10-03
Dong-A ST–Beactica: cancer drugs, 201610– collab + license agreem multi-year drug development 2016-10-01
Onxeo–Financière de la Montagne: investment, 201609 capital increase €12.5m incl €1.7m from FdlM keeping its position as largest shareholder w 13.65% 2016-09-29
Onxeo–SEVERAL: investment, 201609 capital increase €12.5m with 5.4m new ordinary shares at €2.3/share to US + European institutional investors 2016-09-29
Euformatics–SEVERAL: investment, 201609 seed financing round €350k from Tekes + angel investors 2016-09-20
Organobalance–Novo Group: investment, 201609 acquisition €na of Organobalance GmbH by Novozymes 2016-09-15
TATAA Biocenter–Basepair: bioinformatics, 201609– collab TATAA to offer Basepair’s data analysis s/w for NGS 2016-09-13
Rigontec–Boehringer: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor BIVF 2016-09-06
Rigontec–Forbion: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Forbion Capital Partners 2016-09-06
Rigontec–High-Tech Gründerfonds: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor HTGF 2016-09-06
Rigontec–Mitsubishi Chemical: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor MP Healthcare 2016-09-06
Rigontec–North Rhine-Westphalia (govt): investment, 201609 financing round Series A 3rd + final closing totalling €15m w returning investor NRW.BANK 2016-09-06
Rigontec–SEVERAL: investment, 201609 financing round Series A 3rd + final closing €15m from existing investors 2016-09-06
Rigontec–Sunstone Capital: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Sunstone Capital 2016-09-06
Rigontec–Wellington Partners: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Wellington 2016-09-06
Shimadzu–Trivitron: mass spectrometry, 201609– collab newborn screening tests of Labsystems Diagnostics on Shimadzu mass spec systems 2016-09-06
CiToxLab–Andrew Lloyd Associates: public relations, 201609 service existent by ALA 2016-09-01
DiViNe project–Affilogic: vaccine purification technology, 201609 collab Affilogic is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–Aquaporin: vaccine purification technology, 201609 collab Aquaporin is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–EU (govt): grant, 201609c– Horizon 2020 grant 5y to advance vaccine purification led by iBET 2016-09-01
DiViNe project–GSK: vaccine purification technology, 201609 collab GSK Italy is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–iBET (PT): vaccine purification technology, 201609 collab GenIbet + iBET are partners in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–Merck (DE): vaccine purification technology, 201609– collab Merck is partner in Horizon 2020 project led by iBET 2016-09-01
Innovative Medicines Initiative–Lipotype: lipidomics, 201609– collab Lipotype is participant in RHAPSODY project on type 2 diabetes 2016-09-01
Boehringer–Saniona: schizophrenia drugs, 201608– collab reserach €5m upfront + €85m milestones + royalties to identify compounds for schizophrenia 2016-08-29
Trek Therapeutics–Medivir: virostatic agent, 201608– license excl €na ww excl Greater China for nucleotid poylmerase inhibitor MIV-802 2016-08-17
Oculis–SEVERAL: investment, 201608 financing round Series A led by Brunnur Ventures + Silfurberg 2016-08-11
InDex Pharmaceuticals–SEVERAL: investment, 201608–201610 IPO SEK250m at Nasdaq First North in Stockholm 2016-08-01
Thomson Reuters–Onex Corp: investment, 201607–201610 acquisition $3.55b in cash of Thomson Reuters IP + Science business by Onex + Baring PE Asia 2016-07-11
Cormorant Pharmaceuticals–BMS: investment, 201606 acquisition 100% for upfront + near term $95m + $425m milestones 2016-07-05
Brainshake–SEVERAL: investment, 201607 financing round Series A €3.5m led by Cor Group + incl Tekes + Nordea + Finnvera 2016-07-01
Leo Pharma–AstraZeneca: therap antibodies, 201607– excl rights to develop + commercialise tralokinumab + brodalumab in Europe 2016-07-01
Qiagen–Barclays: financial services, 201606 supply financial advisor to Qiagen with regard to offer for Exiqon AS 2016-06-22
MetaSUB project–Qiagen: genomic sample preparation, 201606– collab project using Qiagen sample tech + library prepration workflows 2016-06-21
F2G Ltd–SEVERAL: investment, 201606 financing round $60m led by Sector Asset Management 2016-06-20
NMD Pharma–Denmark (govt): investment, 201606 seed funding round totalling €3m from Lundbeckfonden Emerge + Novo Seeds + Capnova 2016-06-13
next pagenext page 1 2 3 4 5 6 7 8 9 10 11  next pagenext page



Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top